Seminars in Oncology Nursing
Volume 20, Issue 1 , Pages 53-58 , February 2004

Novel therapies

References 

  1. Schubert MM, Williams BE, Lloid ME, et al.  Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer. 1992;69:2469–2477
  2. Sonis ST. Mucositis as a biological process (a new hypothesis for the development of chemotherapy-induced stomatotoxicity). Oral Oncol. 1998;34:39–43
  3. Sonis ST, Peterson DE, McGuire DB, Williams DA. Mucosal injury in cancer patients (new strategies for research and treatment). J Natl Cancer Inst Monogr. 2001;1–54 p29
  4. Kostler WJ, Hejna M, Wenzel C, et al.  Oral mucositis complicating chemotherapy and/or radiotherapy (options for prevention and treatment). CA Cancer J Clin. 2001;51:290–315
  5. Fahlke J, Ridwelski K, Lippert H. High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma. Int J Colorect Dis. 1999;14:128–130
  6. Gabriel DA, Shea T, Wiley J, et al.  Use of amifostine to reduce mucositis following total body irradiation (TBI)-based autotransplants for lymphoma. [abstract] Proc Am Soc Clin Oncol. 2000;19:268A
  7. Mahood DJ, Dose AM, Loprinzi CL, et al.  Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol. 1991;9:449–452
  8. Rocke LK, Loprinze CL, Lee JK, et al.  A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer. 1993;72:2234–2238
  9. Cascinu S, Fideli A, Fidele SL, et al.  Oral cooling (cryotherapy), an effective treatment for prevention of 5-fluorouracil-induced stomatitis. Oral Oncol Eur J Cancer. 1994;30:234–236
  10. Dumonet C, Sonnit A, Bastion Y, et al.  Prevention of high dose L-PAM induced mucositis by cryotherapy. Bone Marrow Transplant. 1994;14:492–494
  11. Souba WW. The gut as a nitrogen-processing organ in the metabolic response to critical illness. Nutr Supp Serv. 1988;8:15–22
  12. Peterson DE, Petit RG. Phase III study (AES-14 in chemotherapy patients at risk for mucositis). [abstract] Proc Am Soc Clin Oncol. 2003;22:2917
  13. Biron P, Sebban C, Gourmet R, et al.  Research controversies in management of oral mucositis. Support Care Cancer. 2000;8:68–71
  14. Shih A, Miaskowski C, Dodd M, et al.  A research review of the current treatments for radiation-induced oral mucositis in patients with head and neck cancer. Oncol Nurs Forum. 2002;29:1063–1078
  15. Wymenga ANM, van der Graaf WTA, Hofstra LS, et al.  Phase I study of transforming growth factor-β3 mouthwashes for prevention of chemotherapy-induced mucositis. Clin Cancer Res. 1999;5:1363–1368
  16. Foncuberta MC, Cagnoni PJ, Brandts CH, et al.  Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. J Immunother. 2001;24:384–388
  17. Barasch A, Peterson DE, Tanzer JM, et al.  Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer. 1995;76:2550–2556
  18. Cowen D, Tardieu C, Schubert MM, et al.  Low energy helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant (results of a double blind randomized trial). Int J Radiat Oncol Biol Phys. 1997;38:697–703
  19. Epstein JB, Silverman S, Paggiarino DA, et al.  Benzydamine HCl for prophylaxis of radiation-induced oral mucositis (results from a multicenter, randomized, double-blind, placebo-controlled clinical trial). Cancer. 2001;15:875–885
  20. Sinclair Pharma LTD. Surrey, England, UK
  21. Smith T. Gelclair (managing the symptoms of oral mucositis). Hosp Med. 2001;62:623–626
  22. Goldberg S  EN3247 Mucositis Prevention Study Group . Safety and tolerability of EN3247 in the prevention of oral mucositis associated with chemotherapy with or without total body irradiation (Results of a randomized, double-blind, placebo-controlled trial). [abstract] Proc Am Soc Clin Oncol. 2003;22:3097
  23. Gibson RJ, Keefe DM, Clarke JM, et al.  The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chem Pharmacol. 2002;50:53–58
  24. Gibson RJ, Keefe DM, Thompson FM, et al.  Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci. 2002;47:2751–2757
  25. Gibson RJ, Bowen JM, Inglis MRB, et al.  Irinotecan causes severe small intestinal damage as well as colonic damage in the rat with implanted breast cancer. J Gastroenterol Hepatol. 2003;18:1095–1100
  26. Keefe DMK. The effect of cytotoxic chemotherapy on the mucosa of the small intestine. Adelaide: Department of Medicine, University of Adelaide; 1998;
  27. Farrell CL, Bready JV, Rex KL. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res. 1998;58:933–939
  28. Khan WB, Shui C, Ning S, et al.  Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor. Radiat Res. 1997;148:248–253
  29. Klimberg VS, Pappas AA, Nwokedi E, et al.  Effect of supplemental dietary glutamine on methotrexate concentrations in tumors. Arch Surg. 1992;127:1317–1320
  30. Sonis ST, Van Vugt AG, Brien JP, et al.  Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Oral Oncol. 1997;33:47–54
  31. Sonis ST, Peterson RL, Edwards LJ, et al.  Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol. 2000;36:373–381
  32. Sonis ST, Van Vugt AG, McDonald J, et al.  Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters. Cytokine. 1997;9:605–612
  33. Rubin JS, Bottaro DP, Chedid M, et al.  Keratinocyte growth factor. Cell Biol Intl. 1995;19:399–411
  34. Takahashi M, Ota S, Nishimura S, et al.  Keratinocyte growth factor is an endogenous stimulant of rabbit gastric epithelial cell proliferation and migration in primary culture. J Gastroenterol Hepatol. 1996;11:1089–1096
  35. Farrell CL, Rex KL, Chen JN, et al.  The effects of keratinocyte growth factor in preclinical models of mucositis. Cell Prolif. 2002;35(suppl 1):78–85
  36. Klimberg VS, Salloum RM, Kasper M, et al.  Oral glutamine accelerates healing of the small intestine and improves outcome after whole abdominal radiation. Arch Surg. 1990;125:1040–1045
  37. Klimberg VS, Souba WW, Dolson DJ, et al.  Prophylactic glutamine protects the intestinal mucosa from radiation injury. Cancer. 1990;66:62–68
  38. Okuno SH, Woodhouse CL, Loprinzi CL. Phase III placebo-controlled clinical trial evaluation of glutamine for decreasing mucositis in patients receiving 5FU (fluorouracil)-based chemotherapy. [abstract] Proc Am Soc Clin Oncol. 1998;17:256
  39. Wakefield LM, Thompson NL, Flanders KC, et al.  Transforming growth factor-b (multifunctional regulator of cell growth and phenotype). Ann NY Acad Sci. 1996;290–298
  40. Potten CS, Booth D, Haley JD. Pretreatment with transforming growth factor beta-3 protects small intestinal stem cells against radiation damage in vivo. Br J Cancer. 1997;75:1454–1459
  41. Du XX, Williams DA. Interleukin-11 (a multifunctional growth factor derived from the hematopoietic microenvironment). Blood. 1994;83:2023–2030
  42. Du XX, Neben DT, Goldman S, et al.  Effects of recombinant human interleukin-11 on hematopoietic reconstitution in transplant mice (acceleration of recovery of peripheral blood neutrophils and platelets). Blood. 1993;81:27–34
  43. Du XX, Doerschuk CM, Orazi A, et al.  A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood. 1994;83:33–37
  44. Potten CS. Interleukin-11 protects the clonogenic stem cells in murine small-intestinal crypts from impairment of their reproductive capacity by radiation. Intl J Cancer. 1995;62:356–361
  45. Antonadou D, Coliarakis N, Synodinou M, et al.  Randomized phase III trial of radiation treatment +/− amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:915–922
  46. Senzer N. A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification (preliminary findings). Semin Radiat Oncol. 2002;29:38–41
  47. Leong SS, Tan EH, Fong KW, et al.  Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2003;21:1767–1774
  48. Kouvaris J, Kouloulias V, Malas E, et al.  Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy. Strahlenther Onkol. 2003;179:167–174
  49. Athanassious H, Antonadou D, Coliarakis N, et al.  Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas (results of a randomized trial). Int J Radiat Oncol Biol Phys. 2003;56:1154–1160
  50. Ben-Joseph E, Han S, Tobi M, et al.  Intrarectal application of amifostine for the prevention of radiation-induced rectal injury. Semin Radiat Oncol. 2002;12:81–85

PII: S0749-2081(03)00140-2

doi: 10.1053/j.soncn.2003.10.009

Seminars in Oncology Nursing
Volume 20, Issue 1 , Pages 53-58 , February 2004

Article Tools